BioCentury
ARTICLE | Clinical News

Anthim obiltoxaximab: Phase III data

October 13, 2014 7:00 AM UTC

Elusys said data from a double-blind, placebo-controlled, U.S. Phase III trial in 280 healthy adult volunteers support the safety and tolerability of single 16 mg/kg dose of IV obiltoxaximab. The most common adverse events related to obiltoxaximab reported were pruritus and headache. The most common hypersensitivity events reported were pruritus, rash and urticaria. Elusys plans to submit a BLA to FDA for obiltoxaximab in 1Q15. ...